Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
Bordin V, Giani L, Meregalli S, Bukovec R, Vaghi MM, Mandalà M, Paolorossi F, Ardizzoia A, Tancini G, Barni S, Frigerio F, Fumagalli L, Bordoni A, Valsuani G, Di Felice G, Lissoni P.
Bordin V, et al. Among authors: mandala m.
Urol Int. 2000;64(1):3-8. doi: 10.1159/000030473.
Urol Int. 2000.
PMID: 10782024
Clinical Trial.